SAŽETAK UVOD: Antikoagulantna terapija direktnim oralnim antikoagulansima (DOAK) je
prema savremenim vodičima apsolutna preporuka za nastavak lečenje pacijenata sa …

Oral anticoagulants are effective in prevention and treatment of thromboembolism, but
despite refinements and standardization in their use, many problems remain for clinicians …

Thromboembolic disease (TD) is a relatively common disease with acute risk of death and
potential long-term consequences in term of postthrombotic syndrome or chronic pulmonary …

Introduction: Over the past 15 years, direct oral anticoagulant (DOAC) drugs have replaced
vitamin K antagonists in a number of indications requiring oral anticoagulant therapy …

Терапија директним оралним антикоагулансима (ДОАК) је према савременим
водичима препоручена за лечење пацијената са плућном тромбоемболијом (ПТЕ) …

Peripheral arterial disease (PAD) is a disease of the arteries of the lower extremities and
represents a global health problem with an increasing prevalence rate. Evidence for the use …

Sažetak Uloga antikoagulantne terapije u liječenju ishemijskoga moždanog udara
posljednjih se godina značajno mijenja. Iako je u primjeni u toj indikaciji već više od 50 …

Background: Direct oral anticoagulants (DOACs) have been used in acute pulmonary
thromboembolism as an alternative to warfarin due to drug interactions, narrow therapeutic …

Pulmonary embolism (PE) is the third most common cardiovascular disease after myocardial
infarction and stroke, and one of the leading causes of death in Europe. Aim. Analysis of the …

The aim is to analyze how the advances in pulmonary thromboembolism (PTE) may
influence its therapeutic protocol, focusing on the anti-vitamin K (AVK) start. Narrative review …